Molecular Partners (MOLN) Stock Price, News & Analysis

Company Overview

Molecular Partners AG is a clinical-stage biotechnology company based in Zurich, Switzerland. The company develops medicines using its proprietary DARPin platform, which is based on designed ankyrin repeat proteins. These engineered proteins are intended to bind selectively to therapeutic targets and can be assembled into multi-specific molecules designed to address complex diseases.

Molecular Partners focuses primarily on oncology and other serious diseases, including immunological and infectious conditions. Its research and development programs are designed to modulate the tumor microenvironment, engage immune cells, and target disease-related proteins. The company’s pipeline has included investigational oncology candidates such as MP0310 and MP0533, as well as ensovibep, an antiviral DARPin developed for coronavirus infections.

Founded in 2004, Molecular Partners conducts research and clinical development from Switzerland and collaborates with pharmaceutical and biotechnology companies to advance its drug candidates. The company is listed on the Nasdaq Global Select Market under the symbol MOLN and maintains an international focus through its clinical development activities and strategic partnerships.

Key Stats

• Today's Range: $4.30 to $4.30
• 50-Day Range: $3.77 to $4.61
• 52-Week Range: $3.53 to $5.36
• Volume: 286 shs
• Average Volume: 1,490 shs
• Market Capitalization: $162.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.38
• Consensus Rating: Hold

Molecular Partners Stock Analysis - MarketRank™

Molecular Partners scored higher than 37% of companies evaluated by MarketBeat, and ranked 680th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Molecular Partners has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Molecular Partners has a consensus price target of $8.38, representing about 94.8% upside from its current price of $4.30.

Amount of Analyst Coverage

Molecular Partners has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Molecular Partners are expected to grow in the coming year, from ($1.28) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Molecular Partners is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Molecular Partners is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Molecular Partners has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Molecular Partners has been sold short.

Short Interest Ratio / Days to Cover

Molecular Partners has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Molecular Partners has recently increased by 17.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Molecular Partners does not currently pay a dividend.

Dividend Growth

Molecular Partners does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Molecular Partners this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Molecular Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.93% of the stock of Molecular Partners is held by insiders.

Percentage Held by Institutions

26.55% of the stock of Molecular Partners is held by institutions.

Company Calendar

• Last Earnings: 8/25/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MOLN
• CIK: 1745114
• Web: www.molecularpartners.com
• Phone: 41-44-755-7700
• Fax: N/A
• Employees: 134
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Molecular Partners: $8.38
• High Price Target: $13.00
• Low Price Target: $3.75
• Potential Upside/Downside: +107.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -68.36%
• Return on Assets: -54.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: $5.65 million
• Price / Sales: 28.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.40 per share
• Price / Book: 1.68

Miscellaneous

• Outstanding Shares: 40,380,000
• Free Float: 37,981,000
• Market Cap: $162.93 million
• Optionable: Not Optionable
• Beta: 1.09